Search

  • HOME
  • Search
Letter to the Editor
1878
Changing from NAFLD to MASLD: Similar prognosis of patients with HCC under atezolizumab/bevacizumab treatment between NAFLD and MASLD
Hiroyuki Suzuki, Shigeo Shimose, Hideki Iwamoto, Takashi Niizeki, Takumi Kawaguchi
Clin Mol Hepatol. 2024;30(2):263-265.   Published online January 18, 2024
View: 1653   Download: 112
Review
1774
Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversity
Hideki Iwamoto, Shigeo Shimose, Tomotake Shirono, Takashi Niizeki, Takumi Kawaguchi
Clin Mol Hepatol. 2023;29(3):593-604.   Published online February 13, 2023
View: 3739   Download: 318  Web of Science: 6  Crossref: 8
Letter to the Editor
1672
Clinical significance of the discrepancy between radiological findings and biochemical responses in atezolizumab plus bevacizumab for hepatocellular carcinoma
Hideki Iwamoto, Shigeo Shimose, Takashi Niizeki, Hironori Koga, Takuji Torimura
Clin Mol Hepatol. 2022;28(3):575-579.   Published online April 21, 2022
View: 3284   Download: 203  Web of Science: 6  Crossref: 6
1631
Impact of branched-chain amino acids and frailty on the management of lenvatinib-related fatigue in patients with hepatocellular carcinoma
Shigeo Shimose, Shunji Koya, Takumi Kawaguchi, Keisuke Hirota, Sachiyo Yoshio, Takashi Niizeki, Hiroo Matsuse, Takuji Torimura
Clin Mol Hepatol. 2021;27(4):616-619.   Published online September 13, 2021
View: 4846   Download: 201  Web of Science: 3  Crossref: 3
1 |

Clinical and
Molecular
Hepatology

Print ISSN: 2287-2728
Online ISSN: 2287-285X


Editorial Office
The Korean Association for the Study of the Liver
Room A1210, 53 Mapo-daero(MapoTrapalace, Dowha-dong), Mapo-gu, Seoul, 04158, Korea
TEL: +82-2-703-0051   FAX: +82-2-703-0071    E-mail: kasl@kams.or.kr
Copyright © The Korean Association for the Study of the Liver.         
COUNTER
TODAY : 1824
TOTAL : 1849851
Close layer